Companies

Voyager Therapeutics, Inc. (VYGR) SEC filings

CIK 0001640266 · Biological Products, (No Diagnostic Substances) (SIC 2836) · Nasdaq · incorporated in DE · fiscal year ends 12/31

Annual financials (from the company's own XBRL in its 10-K filings)

FY2025FY2024FY2023FY2022
Revenue (USD)40.4 M40.9 M
Net income (USD)-46.4 M-71.2 M36.7 M
Diluted EPS (USD/shares)-2.04-1.21

Latest filings

FiledFormDescriptionPeriod
2026-10-218-K8-K items 5.02,9.012026-10-20
2026-08-14SCHEDULE 13G/ASCHEDULE 13G/A
2026-08-068-K8-K items 2.02,9.012026-08-06
2026-08-0610-Q10-Q2026-06-30
2026-07-31SCHEDULE 13G/ASCHEDULE 13G/A
2026-07-138-KFORM 8-K items 8.012026-07-13
2026-06-114OWNERSHIP DOCUMENT2026-06-09
2026-06-114OWNERSHIP DOCUMENT2026-06-09
2026-06-114OWNERSHIP DOCUMENT2026-06-09
2026-06-114OWNERSHIP DOCUMENT2026-06-09
2026-06-114OWNERSHIP DOCUMENT2026-06-09
2026-06-114OWNERSHIP DOCUMENT2026-06-09
2026-06-114OWNERSHIP DOCUMENT2026-06-09
2026-06-114OWNERSHIP DOCUMENT2026-06-09
2026-06-114OWNERSHIP DOCUMENT2026-06-09
2026-06-108-KFORM 8-K items 5.03,5.07,9.012026-06-09
2026-06-018-KFORM 8-K items 8.012026-06-01
2026-05-183OWNERSHIP DOCUMENT2026-05-08
2026-05-15144144
2026-05-15SCHEDULE 13G/ASCHEDULE 13G/A
2026-05-15SCHEDULE 13G/ASCHEDULE 13G/A
2026-05-15144144
2026-05-078-K8-K items 2.02,9.012026-05-07
2026-05-0710-Q10-Q2026-03-31
2026-04-28ARSARS2025-12-31

Forms on file (last 1,000): 4 272, 8-K 113, 144 42, SC 13G/A 40, 3 38, 10-Q 33, SC 13G 18, SCHEDULE 13G/A 13. Source: SEC EDGAR, as filed; this page is public data and not investment advice.

For software and AI agents: the same data as JSON, per call, no account: GET https://store.agentexchange.work/gw/filings/company?ticker=VYGR (0.002 USD), /gw/filings/filings?ticker=VYGR&form=8-K, /gw/filings/facts?ticker=VYGR&concept=Revenues, full-text /gw/filings/search?q=.... Pay per call in USDC (x402) or with a 19 USD card key for 1,000 calls. Catalogue · llms.txt

Updated from EDGAR within 30 minutes of a filing. Agent Exchange